[
  {
    "title": "Guidance for Industry: E6(R2) Good Clinical Practice",
    "agency": "FDA",
    "year": 2023,
    "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1",
    "summary": "This guidance provides updated standards for the conduct of clinical trials of medical products.",
    "relevance_score": 0.95,
    "tags": [
      "GCP",
      "clinical trials",
      "quality",
      "ethics"
    ]
  },
  {
    "title": "Enhancing the Diversity of Clinical Trial Populations",
    "agency": "FDA",
    "year": 2023,
    "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial",
    "summary": "This guidance provides recommendations to sponsors on approaches to increasing diversity in clinical trial populations.",
    "relevance_score": 0.9,
    "tags": [
      "diversity",
      "inclusion",
      "clinical trials",
      "enrollment"
    ]
  },
  {
    "title": "Adaptive Designs for Clinical Trials of Drugs and Biologics",
    "agency": "FDA",
    "year": 2022,
    "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry",
    "summary": "This guidance describes adaptive design principles for clinical trials and provides recommendations for their implementation.",
    "relevance_score": 0.85,
    "tags": [
      "adaptive design",
      "clinical trials",
      "statistical methods"
    ]
  },
  {
    "title": "Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products",
    "agency": "EMA",
    "year": 2023,
    "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf",
    "summary": "This guideline provides strategies to calculate the first dose in humans, dose escalation, and risk mitigation for early phase trials.",
    "relevance_score": 0.93,
    "tags": [
      "Phase 1",
      "first-in-human",
      "dose escalation",
      "risk mitigation",
      "safety"
    ]
  },
  {
    "title": "ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials",
    "agency": "EMA",
    "year": 2022,
    "url": "https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials",
    "summary": "This guideline provides a framework to align clinical trial planning, design, conduct, analysis, and interpretation.",
    "relevance_score": 0.9,
    "tags": [
      "estimands",
      "statistical analysis",
      "clinical trials",
      "ICH"
    ]
  },
  {
    "title": "Guideline on the evaluation of anticancer medicinal products in man",
    "agency": "EMA",
    "year": 2023,
    "url": "https://www.ema.europa.eu/en/evaluation-anticancer-medicinal-products-man",
    "summary": "This guideline addresses methodological considerations for the development of anticancer medicinal products.",
    "relevance_score": 0.87,
    "tags": [
      "oncology",
      "anticancer",
      "clinical development",
      "efficacy endpoints"
    ]
  },
  {
    "title": "Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis",
    "agency": "EMA",
    "year": 2022,
    "url": "https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-multiple-sclerosis",
    "summary": "This guideline provides specific considerations for clinical trials in multiple sclerosis.",
    "relevance_score": 0.82,
    "tags": [
      "multiple sclerosis",
      "neurology",
      "clinical trials",
      "endpoint selection"
    ]
  },
  {
    "title": "Basic Principles on Global Clinical Trials",
    "agency": "PMDA",
    "year": 2023,
    "url": "https://www.pmda.go.jp/files/000156939.pdf",
    "summary": "This document outlines considerations for conducting global clinical trials including Japanese subjects.",
    "relevance_score": 0.88,
    "tags": [
      "global clinical trials",
      "multiregional",
      "Japan",
      "ethnicity factors"
    ]
  },
  {
    "title": "Points to Consider for Drug Master Files",
    "agency": "PMDA",
    "year": 2022,
    "url": "https://www.pmda.go.jp/english/review-services/regulations-standards/0009.html",
    "summary": "This document provides guidance on preparation and submission of Drug Master Files in Japan.",
    "relevance_score": 0.75,
    "tags": [
      "drug master file",
      "chemistry manufacturing controls",
      "Japan",
      "quality"
    ]
  },
  {
    "title": "Technical Guidelines for Clinical Trials of Drugs in China",
    "agency": "NMPA",
    "year": 2023,
    "url": "https://english.nmpa.gov.cn/",
    "summary": "These guidelines provide technical requirements for conducting clinical trials in China.",
    "relevance_score": 0.85,
    "tags": [
      "China",
      "clinical trials",
      "NMPA",
      "regulatory requirements"
    ]
  },
  {
    "title": "Guidelines for Acceptance of Overseas Clinical Trial Data",
    "agency": "NMPA",
    "year": 2022,
    "url": "https://english.nmpa.gov.cn/",
    "summary": "This document provides guidance on the acceptance of foreign clinical trial data for drug registration in China.",
    "relevance_score": 0.83,
    "tags": [
      "China",
      "foreign data",
      "clinical trials",
      "drug registration"
    ]
  },
  {
    "title": "CONSORT 2024 Statement: Updated Guidelines for Reporting Randomized Trials",
    "agency": "Academic",
    "year": 2024,
    "url": "https://www.consort-statement.org/",
    "summary": "These updated guidelines provide best practices for reporting randomized controlled trials to ensure transparency and reproducibility.",
    "relevance_score": 0.92,
    "tags": [
      "reporting guidelines",
      "randomized trials",
      "transparency",
      "academic",
      "publication"
    ]
  },
  {
    "title": "SPIRIT 2022 Statement: Standard Protocol Items for Clinical Trials",
    "agency": "Academic",
    "year": 2022,
    "url": "https://www.spirit-statement.org/",
    "summary": "This academic guidance provides recommendations for minimum protocol items to include when designing clinical trials.",
    "relevance_score": 0.9,
    "tags": [
      "protocol design",
      "academic",
      "methodology",
      "clinical trial standards"
    ]
  },
  {
    "title": "Clinical Trials 2.0: A Vision for More Efficient, Informative, and Ethical Clinical Trials",
    "agency": "Academic",
    "year": 2023,
    "url": "https://www.nejm.org/",
    "summary": "This academic paper outlines a vision for next-generation clinical trials that are more efficient, participant-centered, and generate higher quality evidence.",
    "relevance_score": 0.87,
    "tags": [
      "clinical trial design",
      "innovation",
      "efficiency",
      "patient-centricity",
      "academic"
    ]
  }
]